Comparison of Effectiveness of Sacubitril plus Valsartan versus Ramipril in Post MI Chronic Left Ventricular Systolic Heart Failure Patients with Reduced Ejection Fraction


PDF PDF

Keywords

Sacubitril plus Valsartan
Ramipril
Post MI
Chronic Left Ventricular Systolic Heart Failure
Ejection Fraction

How to Cite

1.
Comparison of Effectiveness of Sacubitril plus Valsartan versus Ramipril in Post MI Chronic Left Ventricular Systolic Heart Failure Patients with Reduced Ejection Fraction. The Insight [Internet]. 2026 Nov. 15 [cited 2026 Nov. 17];9(03):887-91. Available from: https://bdjournals.org/insight/article/view/1652

Abstract

Background: Heart failure is an increasing worldwide issue impacting 1-2% of the population and over 10% of older adults, resulting in high mortality rates. It is categorized by LVEF into HFrEF, HFmrEF, and HFpEF. Ramipril is effective but can lead to cough and kidney/electrolyte issues, whereas sacubitril+valsartan demonstrates improved results in HFrEF with increased hypotension. This study assesses both medications because of restricted local information. Methods & Materials: This study was a forward-looking comparative clinical trial carried out at Sir Salimullah Medical College and Mitford Hospital in Dhaka (January 2018-June 2019). A total of 100 post-MI HFrEF patients were randomly allocated to receive either sacubitril+valsartan or ramipril (50 each) and monitored for 3 months. Results showed enhancement in HF status and EF, with additional outcomes related to mortality, rehospitalization, medication discontinuation, and safety evaluation. Results: The baseline characteristics were comparable in both groups. Sacubitril+valsartan exhibited a more significant enhancement in NYHA class and EF, with fewer individuals in class III-IV (40% vs. 75%, p = 0.018) and an increased EF (34.96 ± 2.98 vs. 33.12 ± 3.32, p = 0.104). It also decreased rehospitalizations (6% compared to 22%, p = 0.018) and mortality rates (4% against 8%, p = 0.025), but resulted in higher hypotension incidence (18% compared to 8%). Other negative effects were reduced in the sacubitril+valsartan group (p = 0.027). Conclusion: Sacubitril+valsartan significantly improved NYHA functional class compared to ramipril after 3 months in post-MI HFrEF patients. It also showed lower rates of secondary outcomes and overall complications in patients received Sacubitril plus Valsartan.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2026 The Insight